Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy Participants
Clinical Pharmacology in Drug Development · 2025-02 · 14 (2) · 91-104
DOI: 10.1002/cpdd.1491 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 22.12.2024. Verfasst von Jianke Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Gossamer Bio, Inc., San Diego, CA, USA. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Seralutinib, an inhaled, small‐molecule tyrosine kinase inhibitor in clinical development for the treatment of pulmonary arterial hypertension (PAH), was evaluated for its potential as a perpetrator or victim of a metabolic and transporter‐based drug‐drug interactions in 2 phase 1 studies. In study 1, 24 participants received a cocktail of probe substrates: caffeine (CYP1A2), montelukast (CYP2C8), flurbiprofen (CYP2C9), midazolam (CYP3A), and pravastatin (OATP1B1/1B3), plus digoxin (P‐gp) with or without seralutinib. In study 2, 19 participants received seralutinib with/without itraconazole, a strong CYP3A inhibitor, or fosaprepitant, a weak CYP3A inhibitor. Geometric least‐squares mean ratios and 90% confidence intervals for maximum observed concentration (C max ) and area under the plasma concentration‐time curve (AUC) were obtained. Safety was monitored throughout the studies. All adverse events were mild or moderate in severity. Seralutinib coadministration increased AUC for midazolam 3.03‐fold and caffeine 1.32‐fold. The coadministration increased digoxin C max 1.28‐fold. Seralutinib did not meaningfully alter C max and AUC for montelukast, flurbiprofen, or pravastatin. Fosaprepitant and itraconazole increased seralutinib AUC 1.08‐ and 1.84‐fold, respectively. Seralutinib is a moderate CYP3A inhibitor and a weak CYP1A2 inhibitor; it slightly inhibits P‐gp. Seralutinib exposure is minimally affected by a weak CYP3A inhibitor but is substantially increased by a strong CYP3A inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gossamer Bio, Inc., San Diego, CA, USA.
- ICON Early Phase Service, San Antonio, TX, USA.
Zitieren
APA
Li, J., Parsley, E., Cravets, M., DeNoia, E., Key, C., & Mathias, A. (2025). Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy Participants. Clinical Pharmacology in Drug Development, 14(2), 91-104. https://doi.org/10.1002/cpdd.1491
Vancouver
Li J, Parsley E, Cravets M, DeNoia E, Key C, Mathias A. Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy Participants. Clinical Pharmacology in Drug Development. 2025;14(2):91-104. doi:10.1002/cpdd.1491
BibTeX
@article{Li2025,
author = {Li, Jianke and Parsley, Ed and Cravets, Matt and DeNoia, Emanuel and Key, Cassandra and Mathias, Anita},
title = {Phase 1 Studies to Assess Inhaled Seralutinib as a Perpetrator or a Victim of Drug‐Drug Interactions in Healthy Participants},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
volume = {14},
number = {2},
pages = {91--104},
doi = {10.1002/cpdd.1491}
}
EUVIMED